admin April 20, 2025
BioCell Innovations Pte Ltd, a Singapore-based biotechnology company pioneering next-generation CAR-T therapies, announced today that it has been awarded a G-Rex® Grant (USD$125,000) from ScaleReady to integrate our proprietary CAR manufacturing process with the highly efficient G-Rex platform.
BioCell Innovations has introduced a proprietary CAR-T manufacturing process that dramatically reduces cytokine-associated toxicities, particularly cytokine release syndrome (CRS), without compromising therapeutic potency. This next-generation platform delivers a cost-effective, scalable, and clinically adaptable solution, prioritizing both patient safety and treatment efficacy.
“With the support of this grant, we aim to seamlessly integrate our manufacturing process into the G-Rex system — accelerating the clinical deployment of a safer and more effective CAR-T product,” said Dr. Paula Lam, Chief Scientific Officer at BioCell Innovations.
“Optimizing CAR-T manufacturing is more than scientific innovation; it’s a commitment to accessibility. The G-Rex Grant empowers us to refine and scale BC-003 production, enhancing efficiency expanding access to innovative immunotherapies to more patients in need” added Dr. Fazil Turabe, Head of Research & Development.
“We are eager to collaborate with BioCell on their BC-003 CAR-T asset to develop a streamlined, cost-effective, manufacturing process that will allow for these innovative therapies to be accessible to a broader patient population,” said Josh Ludwig, Global Commercial Director of ScaleReady. “This G-Rex Grant will be the catalyst that allows BioCell’s innovative immunotherapies to more patients”
The G-Rex Grant Program is a $20M initiative launched by ScaleReady in collaboration with Wilson Wolf Manufacturing. It aims to accelerate innovation in cell and gene therapy (CGT) development, and thus supporting companies like BioCell to deliver real-world solutions through precise CAR-T manufacturing.
About BC-003
BC-003 is a dual targeting CD19-CD20 CAR-T product designed to target B-cell malignancies, including relapsed and refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. By simultaneously engaging CD19 and CD20, BC-003 aims to overcome antigen escape mechanisms and improve therapeutic efficacy.
About BioCell Innovations Pte Ltd
BioCell Innovations is a Singapore-based biotechnology company developing next-generation CAR-T and immune cell therapies. The company specializes in process optimization, vector engineering, and immune cell expansion, with a mission to create safer, more effective, and economically viable cell therapies for cancer treatment. BioCell Innovations collaborates with leading biopharmaceutical companies, research institutions, and clinical partners to advance its pipeline of novel CAR-T products. For more information, visit: https://www.biocell.com.sg/
About ScaleReady™
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world’s most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady’s expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex® technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf’s mission is to create hope for cancer patients, one G-Rex device at a time.
